Excited to present today at prestigious Late-Breaking Science forum at the @escardio #HeartFailure2022, first clinical data of the VECTOR-HF I study which confirms the safety and accuracy of V-LAP in heart microcomputer for remote management of #HeartFailure
@OranKoren @DDamario
In a great presentation and discussion today at #europcr2022, Dr. Eyal Orion, MD discussed how Vectorious is transforming #heartfailure treatment paradigms by allowing patients to remotely monitor their LA pressure via the V-LAP app and take ownership of their disease
1
Pleasure to be part of #InnovationDublin22! Earlier today Eyal Orion, MD presented the VECTOR-HF II study and how our unique patient self-management approach empowers #heartfailure patients to take control of their disease and improves #patientcare!
@MedTechStrat
We've enrolled the first 6 patients in the VECTOR-HF II Study! These #heartfailure patients will have full visibility of their hearts’ LA pressure via the V-LAP app & can self-adjust their medication to stop further deterioration & avoid hospitalizations. ow.ly/aA3250ITvAH
For the first time in two years, #InnovationDublin22, Europe's largest #medtech partnering and investment conference is back! If you're nearby come hear the latest developments in the VECTOR-HF study! Thursday 28, 2022 09:15-09:25 @MedTechStrat
Excited to attend the first-ever Technology and Heart Failure Therapeutics ( #THT2022) meeting in NYC and present the ongoing development of our clinical data about the role of personalized LAP management in #heartfailure patients using the V-LAP system.
2
#WorldHeartDay reminds us that #cardiovascular diseases (CVDs) are still the #1 killer among adults worldwide.
With a joint effort of the medical community, entrepreneurs, tech companies, and scientists, will we succeed in eradicating the greatest epidemic in the world.
Amazing news for Vectorious' V-LAP and for all FDA's #Breakthroughdevices and a HUGE WIN for the millions of patients around the world that will soon have faster access to the latest #medicaldevices innovations!
go.cms.gov/2LMo5Mk
@CMSGov @FDADeviceInfo
A case study by #Vivnates team which demonstrates the V-LAP's value in treating and stabilizing a German #heartfailure patient remotely, while in self-isolation during the #COVID19.
Reamote healthcare is no longer a privilege. It's here to stay.
https://nitter.cf/t.co/MmQWzLUf8I @ehj_ed
Exciting day for Vectorious!
A vote of confidence by the @US_FDA in the V-LAP potential to significantly upgrade #heartfailure management and treatment and the clear benefits of left atrial pressure (LAP)-based therapy!
lnkd.in/eZkniMj
1













